Author

Justin Shang

Observed institution: Autolus (United Kingdom)

OpenAlex ID: A5041534366

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

2024 · Kate Cwynarski, Gloria Iacoboni, et al. · Nature Medicine · 47

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

2022 · Kate Cwynarski, Gloria Iacoboni, et al. · Blood · 28

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia

2026 · Elias Jabbour, Karamjeet S. Sandhu, et al. · Haematologica · 6

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

2024 · Claire Roddie, Jae H. Park, et al. · Blood · 1

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

2024 · Jae H. Park, Elias Jabbour, et al. · Blood · 1

ALL-502 Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study

2024 · Elias Jabbour, Karamjeet S. Sandhu, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Quality of Life in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Obecabtagene Autoleucel (obe-cel) in the Pivotal Phase 2 Felix Study

2024 · Karamjeet S. Sandhu, Jean A. Yared, et al. · Transplantation and Cellular Therapy · 1

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia

2026 · Max S. Topp, Bijal D. Shah, et al. · Leukemia

Treatment of Pediatric Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia with Obecabtagene autoleucel, a CD19-Directed Chimeric Antigen Receptor T-cell Therapy: Preliminary Findings from the Phase Ib/II CATULUS Trial

2026 · Sara Ghorashian, Michael A Pulsipher, et al. · Transplantation and Cellular Therapy

Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy: Preliminary findings from the Phase Ib/II CATULUS trial

2025 · Sara Ghorashian, Michael Pulsipher, et al. · Blood

Comparison of Obecabtagene Autoleucel (obe-cel) Versus an External Control Arm (ECA) in Adult Patients (pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

2025 · Max S Topp, Bijal D Shah, et al. · Transplantation and Cellular Therapy

Risk Factors Associated with Sub-Optimal Outcomes and Hematotoxicity Following Obecabtagene Autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

2025 · Karamjeet S Sandhu, Jae H Park, et al. · Transplantation and Cellular Therapy

Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study

2024 · Elias Jabbour, Karamjeet S. Sandhu, et al. · Clinical Lymphoma Myeloma & Leukemia

S262: Safety and Efficacy of Obecabtagene Autoleucel (obe-cel), a Fast-off Rate Cd19 Car in Relapsed/refractory Adult B-cell Acute Lymphoblastic Leukaemia:top Line Results of the Pivotal Felix Study

2023 · Claire Roddie, Karamjeet Sandhu, et al. · HemaSphere

Erratum to: “Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia”

2020 · Elias Jabbour, Karamjeet S. Sandhu, et al. · Haematologica

Works count: 15

Citation count: 83

H-index: 3

I10-index: 2